KalVista reports early EKTERLY sales momentum, rising prescriber adoption and global regulatory approvals following the drug's 2025 launch.
Investing.com -- KalVista Pharmaceuticals Inc (NASDAQ:KALV) stock surged 16.9% in after-hours trading Thursday following the ...
Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. The stock rose 14%, to $17.99, in ...
Stocktwits on MSN
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart
KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
As of Friday, January 09, KalVista Pharmaceuticals, Inc.’s KALV share price has surged by 15.23%, which has investors ...
Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.
Allergic reactions experienced by children were erythematous rash or itching (31%), hives (15.8%), angioedema (12.8%), ...
Children and adults with Prader-Willi syndrome who previously received once-daily diazoxide choline extended-release tablets ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback